PuraMed BioScience Completes the First Production of MigraPure® Gel
SCHOFIELD, Wis., Aug. 13, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCPink:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company has completed its first batch of its patented, sublingual MigraPure® gel containing feverfew and ginger with an enhanced flavor.
"The MigraPure gel formula uses the same concentrations of active ingredients as our LipiGesic® M migraine formulation," said Russell Mitchell, CEO of PuraMed BioScience. "We have responded to consumer feedback regarding the taste and have enhanced the peppermint flavor. The product will be as effective as the LipiGesic M and will have an improved taste."
MigraPure is a doctor-recommended homeopathic formulation of feverfew and ginger that provides highly effective relief of migraine pain and associated symptoms. Packaged in pre-measured UnitDose sachets, MigraPure is administered by placing the gel under the tongue. This delivery method allows the active ingredients of the medication to absorb into the bloodstream within the first few minutes to provide relief rather than the 30 minutes or longer needed for oral medications to absorb through the digestive system.
"We are excited about the rollout of the flavor-enhanced migraine medication, which will also be branded and packaged with a new name, new color scheme and a new price point," said Mitchell. "Since it uses the same clinically tested formulation, we know that MigraPure will stop migraine pain more than 64 percent of the time. [A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesic M*) in the Treatment of Migraines in Headache: The Journal of Head and Face Pain, 2011: 51:1078-1086] It will also relieve migraine-like headaches and self-diagnosed sinus headaches, of which according to the American Migraine Study II, 9 out of 10 are actually undiagnosed migraines.
"Now our product name and packaging will be a better reflection of our all natural, easy-to-use, easy-to-carry migraine relief medication. The new name will be easier for consumers and healthcare providers to remember and recommend. The MigraPure name should make the word-of-mouth component of our marketing efforts more productive," Mitchell added.
"Since our formulation was manufactured a month ahead of schedule, we are making a concerted effort to have our new packaging and website in place as soon as possible so we can execute our marketing and distribution plan," Mitchell said.
MigraPure uses the same sublingual feverfew and ginger gel formula that was clinically tested as LipiGesic® M. Sublingual delivery offers the distinct advantages of faster delivery and efficiency while avoiding the "first-pass effect" that often degrades the effectiveness of oral medications.
The flavor of this homeopathic, all-natural, over-the-counter migraine headache pain relief medication has been enhanced, but the active ingredients that stop disabling migraine pain and associated symptoms quickly, are the same.
MigraPure's feverfew and ginger gel is non-drowsy and non-habit forming. MigraPure is not associated with rebound headaches. According to the clinical trial results published in the July 2011 issue of Headache: The Journal of Head and Face Pain, MigraPure (f/k/a LipiGesic M) has an excellent safety profile and has no reported drug interactions.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.
In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its cannabinoid product line. The first product currently under development is a product to relieve seizure-related headaches.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
SOURCE PuraMed BioScience, Inc.